It looks like they have tried to synthesize a bisantrene equivalent but with limited success. removing the anthracycline ring reduces cardiotoxicity but is this sufficient to then protect against other anthracycline cardiotoxicity - i am doubtful of this. Effectively three versions of the molecules were developed, whilst reduced cardiotoxicity was present - two had no significant anti-cancer effect and the other had liver toxicity issues.
this shows we are officially above the radar and need timelines to go to plan ensure FIC BIC status is maintained. also validates that it is something that others see worthwhile to pursue.
-
- There are more pages in this discussion • 649 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.005(0.44%) |
Mkt cap ! $196.3M | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.12 | $202.7K | 178.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 22685 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 12644 | 3 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| RAC (ASX) Chart |